Delivery Order SPE2DB24D2100-SPE2DB25FBGNF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,855.22 to AmerisourceBergen Drug Corp for XHANCE 93 microgram nasal spray (16 milliliters) on June 18, 2025, with an ultimate completion date of June 20, 2025. This firm fixed price, non-set-aside contract is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $4,033.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XHANCE 93 micrograms nasal spray (16 milliliters) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside award was issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $4,668.46 to AmerisourceBergen Drug Corp for XHANCE 93 MCG Nasal Spray (16ML) on August 8, 2025, with completion scheduled for August 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical supplier within the federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $12,134.11 to supply Xhance 93 MCG nasal spray (16 mL units) with an ultimate completion date of September 18, 2025. This non-competitive delivery order utilizes firm fixed pricing and was awarded on September 17, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under a larger indefinite delivery contract...
- The Defense Logistics Agency awarded a $4,547.56 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for Xhance 93 microgram nasal spray (16 milliliters). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of September 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Xhance 93 microgram nasal spray in 16-milliliter units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing with a ceiling value of $3,180.19 and an ultimate completion date of August 14, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $2,463.62 order is for Xhance 93 mcg nasal spray and has a completion date of March 25, 2024. Amerisourcebergen Drug Corp is the prime contractor on a larger indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00 through December 31,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XHANCE 93 MCG NASAL SPRAY 16ML. The $4,281.82 firm fixed-price delivery order has a completion date of December 10, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $3,086.89 firm-fixed-price delivery order is for the supply of XHANCE 93 MCG Nasal Spray 16ML, with a period of performance through August 23, 2024. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,436.26, is for the delivery of XHANCE 93 MCG Nasal Spray 16ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of December 18, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGNFDelivery Order
The Defense Logistics Agency awarded a $11,725.96 delivery order to AmerisourceBergen Drug Corp for XHANCE 93 MCG nasal spray (16 mL) on September 22, 2025, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving the Defense Health Agency and other military healthcare systems. This delivery order for the nasal spray pharmaceutical falls within the company's extensive portfolio of pharmaceutical products and medical supplies, which includes brand-name and generic medications, vaccines, and specialized healthcare commodities across multiple therapeutic domains. The SPE2DX IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of products to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.7k | 9/22/25 |